Amanda Michelle Buck
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Graduate Student Researcher
Research Areas
Biography and Research Information
OverviewAI-generated summary
Amanda Michelle Buck's research focuses on infectious complications and treatment utilization in patients with relapsed/refractory multiple myeloma. Her recent publication investigates these factors in the context of teclistamab therapy. Buck collaborates with several researchers at the University of Arkansas for Medical Sciences, including Trilok Shrivastava, Maurizio Zangari, Frits van Rhee, and Asis Shrestha, with whom she shares a publication. Her work contributes to understanding the real-world outcomes and management of specific patient populations undergoing advanced cancer therapies.
Metrics
- Publications: 1
Selected Publications
-
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)
Collaboration Network
Top Collaborators
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
Similar Researchers
Based on overlapping research topics